4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast

Core Insights - 4D Molecular Therapeutics (4DMT) is set to present initial interim 24-week landmark analysis data from the Population Extension cohort of the PRISM Phase 2 Clinical Trial for 4D-150, targeting wet age-related macular degeneration (AMD) [1][6] - The presentation will occur at the ASRS Annual Scientific Meeting in Stockholm, Sweden, from July 17-20, 2024, with a webcast scheduled for July 17 at 6:30 a.m. ET [1][6] - The clinical trial involves 45 patients, with specific data on 30 patients treated at a dosage of 3E10 vg/eye expected to be shared [6] Company Overview - 4DMT is a clinical-stage genetic medicines company focused on developing therapies for large market diseases, particularly in ophthalmology and pulmonology [3] - The company utilizes its proprietary Therapeutic Vector Evolution platform, which combines directed evolution technology with synthetic AAV capsid-derived sequences to create customized vectors for its product candidates [3] - Currently, 4DMT is advancing five clinical-stage and two preclinical product candidates, addressing diseases in ophthalmology, pulmonology, and cardiology, along with gene editing programs in CNS [3]